Today on Drug Discovery & Development
EMA begins rolling review of Merck’s and Ridgeback’s COVID-19 pill molnupiravir
Merck (NYSE: MRK) and its partner Ridgeback Biotherapeutics has announced that the European Medicines Agency (EMA) has begun a rolling review for molnupiravir, the experimental antiviral that could be the first oral treatment for COVID-19 to hit the market. Merck has also submitted emergency use authorization (EUA) paperwork related to the drug to FDA. The…
Simplifying safety reporting as part of clinical trial investigator retention
The pharmaceutical industry is like many others today in that there is a high turnover rate. The surge in new clinical trials starting and post-pandemic changes in hiring amplify these concerns for clinical investigators. For example, a 2017 study using the FDA’s Bioresearch Monitoring Information system classified 54.2% of principal investigators as “one-and-done,” meaning they had only…
Drug Discovery and Development See More >
Torx Software bolsters web-based platform for small-molecule drug discovery
Privately-held Torx Software Ltd has expanded its software platform offerings with an automated assay scheduling tool known as Torx Test and compound analysis tool Torx Analyze. Torx offers an internet platform that supports collaboration, knowledge sharing and resource management. In addition, Design-Make-Test-Analyze (DMTA) workflow functionality supports resource management and progress tracking. Torx Test allows chemists…
Sponsored Content See More >
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB Serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
DNA Script launches a benchtop DNA printer
DNA Script announced the commercial launch of its Syntax platform with the Syntax system, a benchtop nucleic acid printer. South San Francisco, Calif.-based DNA Script designed its Syntax system, a fully integrated, automated printer powered by enzymatic DNA synthesis (EDS) technology, to synthesize 96 DNA oligos in parallel, comprised of up to 60 nucleotides in…
Infectious Disease See More >
EMA begins rolling review of Merck’s and Ridgeback’s COVID-19 pill molnupiravir
Merck (NYSE: MRK) and its partner Ridgeback Biotherapeutics has announced that the European Medicines Agency (EMA) has begun a rolling review for molnupiravir, the experimental antiviral that could be the first oral treatment for COVID-19 to hit the market. Merck has also submitted emergency use authorization (EUA) paperwork related to the drug to FDA. The…
Moderna releases positive interim Phase 2/3 COVID-19 vaccine data for children 6 to 11
Pfizer-BioNTech COVID-19 vaccine was 91% effective in 5- to 11-year-olds in Phase 3 study
CDC panel unanimously backs J&J and Moderna vaccine boosters
ACIP votes unanimously backs GSK’s shingles vaccine Shingrix for immunocompromised adults 19 and older
Oncology See More >
SimBioSys secures $15 million in Series A funding for computational oncology software
The developer of a cloud-based application for oncology care and research, SimBioSys, has raised $15 million in Series A funding. Genoa Ventures and Northpond Ventures led the funding round, which also involved AV8 Ventures, Heritage Medical Group, and Mayo Clinic. SimBioSys also announced that existing investors and its founders participated in the financing, raising a total of $21 million. The company…
